- Home
- CISS vs SPRC Comparison
CISS vs SPRC Comparison
Compare CISS & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- SPRC
- Stock Information
- Founded
- CISS 2022
- SPRC 2004
- Country
- CISS Greece
- SPRC Israel
- Employees
- CISS N/A
- SPRC N/A
- Industry
- CISS Marine Transportation
- SPRC Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- SPRC Health Care
- Exchange
- CISS Nasdaq
- SPRC Nasdaq
- Market Cap
- CISS 3.0M
- SPRC 3.5M
- IPO Year
- CISS N/A
- SPRC N/A
- Fundamental
- Price
- CISS $0.50
- SPRC $0.30
- Analyst Decision
- CISS
- SPRC
- Analyst Count
- CISS 0
- SPRC 0
- Target Price
- CISS N/A
- SPRC N/A
- AVG Volume (30 Days)
- CISS 57.1K
- SPRC 6.1M
- Earning Date
- CISS 05-27-2025
- SPRC 02-15-2025
- Dividend Yield
- CISS N/A
- SPRC N/A
- EPS Growth
- CISS N/A
- SPRC N/A
- EPS
- CISS N/A
- SPRC N/A
- Revenue
- CISS $42,296,101.00
- SPRC $1,747,000.00
- Revenue This Year
- CISS N/A
- SPRC N/A
- Revenue Next Year
- CISS N/A
- SPRC N/A
- P/E Ratio
- CISS N/A
- SPRC N/A
- Revenue Growth
- CISS 47.17
- SPRC N/A
- 52 Week Low
- CISS $0.48
- SPRC $0.20
- 52 Week High
- CISS $13.75
- SPRC $2.10
- Technical
- Relative Strength Index (RSI)
- CISS 16.23
- SPRC 39.37
- Support Level
- CISS $0.68
- SPRC $0.27
- Resistance Level
- CISS $0.74
- SPRC $0.39
- Average True Range (ATR)
- CISS 0.04
- SPRC 0.03
- MACD
- CISS 0.00
- SPRC 0.00
- Stochastic Oscillator
- CISS 9.13
- SPRC 27.59
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.